Pfizer announced this Friday that its pill against Covid-19 is 89% effective.
This rate relates to the risk of hospitalization or death, according to the first results of clinical trials.
The company said it intends to provide these results "as soon as possible" to the United States Drugs Agency (FDA) for clearance.
This is the second treatment of this type to show positive results, after the tablet developed by Merck, which was authorized Thursday in a first country, in the United Kingdom.
Antivirals work by decreasing a virus's ability to replicate, thereby slowing down the disease.
Easy to administer, these treatments represent a complement to vaccines to protect against Covid-19.
Read alsoCovid-19: follow the events of the day live
Pfizer's initial results are based on clinical trials on just over 1,200 adults who have contracted Covid-19 and are at risk of developing a severe case of the disease.
Within a few days of onset of symptoms, some were given the Pfizer pill and others received a placebo.
A total of 10 people died among the patients who received the placebo compared with zero deaths in the group who received the treatment.
The company evokes "overwhelming efficiency"
“The interim analysis showed an 89% reduction in the risk of Covid-19 hospitalization and death from any cause compared to placebo in patients treated within three days of symptom onset Pfizer said in a statement. The trial will include a total of 3000 people, but recruitments have now been stopped "in the face of the overwhelming effectiveness" of the treatment in the first results.
"Today's announcement is really a game-changer in our global efforts to stop the devastation caused by this pandemic," said Pfizer boss Albert Bourla, quoted in the press release. “These data suggest that our candidate antiviral therapy, if approved by regulatory authorities, has the potential to save patient lives, reduce the severity of Covid-19 infections, and prevent up to nine out of ten hospitalizations. Pfizer's treatment will be marketed under the name Paxlovid.
Two other clinical trials are currently being carried out by the company.
The first is to assess the effectiveness of the pill in a population not at increased risk of developing a severe case of the disease.
The second tests the ability of the treatment to preventively reduce the risk of infection in those around a person who has contracted the disease.
